Literature DB >> 31371452

The Hajdu Cheney mutation sensitizes mice to the osteolytic actions of tumor necrosis factor α.

Jungeun Yu1,2, Ernesto Canalis3,2,4.   

Abstract

Hajdu Cheney syndrome (HCS) is characterized by craniofacial developmental abnormalities, acro-osteolysis, and osteoporosis and is associated with gain-of-NOTCH2 function mutations. A mouse model of HCS termed Notch2tm1.1Ecan harboring a mutation in exon 34 of Notch2 replicating the one found in HCS was used to determine whether the HCS mutation sensitizes the skeleton to the osteolytic effects of tumor necrosis factor α (TNFα). TNFα injected over the calvarial vault caused a greater increase in osteoclast number, osteoclast surface, and eroded surface in Notch2tm1.1Ecan mice compared with littermate WT controls. Accordingly, the effect of TNFα on osteoclastogenesis was greatly enhanced in cultures of bone marrow-derived macrophages (BMMs) from Notch2tm1.1Ecan mice when compared with the activity of TNFα in control cultures. TNFα induced the expression of Notch2 and Notch2 mutant mRNA by ∼2-fold, possibly amplifying the NOTCH2-dependent induction of osteoclastogenesis. The effect of TNFα on osteoclastogenesis in Notch2tm1.1Ecan mutants depended on NOTCH2 activation because it was reversed by anti-NOTCH2 negative regulatory region and anti-jagged 1 antibodies. The inactivation of Hes1 prevented the TNFα effect on osteoclastogenesis in the context of the Notch2tm1.1Ecan mutation. In addition, the induction of Il1b, but not of Tnfa and Il6, mRNA by TNFα was greater in Notch2tm1.1Ecan BMMs than in control cells, possibly contributing to the actions of TNFα and NOTCH2 on osteoclastogenesis. In conclusion, the HCS mutation enhances TNFα-induced osteoclastogenesis and the inflammatory bone-resorptive response possibly explaining the acro-osteolysis observed in affected individuals.
© 2019 Yu and Canalis.

Entities:  

Keywords:  Hajdu Cheney syndrome; Notch receptor; cytokine; inflammation; osteoclast; osteolysis; tumor necrosis factor (TNF)

Mesh:

Substances:

Year:  2019        PMID: 31371452      PMCID: PMC6768656          DOI: 10.1074/jbc.RA119.009824

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling.

Authors:  T Iso; V Sartorelli; C Poizat; S Iezzi; H Y Wu; G Chung; L Kedes; Y Hamamori
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

2.  ACRO-OSTEOLYSIS.

Authors:  W D CHENEY
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1965-07

3.  The acro-osteolysis syndrome: Morphologic and biochemical studies.

Authors:  D M Brown; D S Bradford; R J Gorlin; R J Desnick; L O Langer; J Jowsey; J J Sauk
Journal:  J Pediatr       Date:  1976-04       Impact factor: 4.406

4.  The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.

Authors:  S E Lee; K M Woo; S Y Kim; H M Kim; K Kwack; Z H Lee; H H Kim
Journal:  Bone       Date:  2002-01       Impact factor: 4.398

5.  Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts.

Authors:  Y Azuma; K Kaji; R Katogi; S Takeshita; A Kudo
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

6.  Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.

Authors:  M Komine; A Kukita; T Kukita; Y Ogata; T Hotokebuchi; O Kohashi
Journal:  Bone       Date:  2001-05       Impact factor: 4.398

7.  Acro-osteolysis and osteoporosis as manifestations of the Hajdu-Cheney syndrome.

Authors:  B T Blumenauer; A B Cranney; R Goldstein
Journal:  Clin Exp Rheumatol       Date:  2002 Jul-Aug       Impact factor: 4.473

Review 8.  HES and HERP families: multiple effectors of the Notch signaling pathway.

Authors:  Tatsuya Iso; Larry Kedes; Yasuo Hamamori
Journal:  J Cell Physiol       Date:  2003-03       Impact factor: 6.384

Review 9.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology.

Authors:  Steeve Kwan Tat; Marc Padrines; Sandrine Théoleyre; Dominique Heymann; Yannick Fortun
Journal:  Cytokine Growth Factor Rev       Date:  2004-02       Impact factor: 7.638

10.  Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Authors:  K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  6 in total

Review 1.  Notch and the regulation of osteoclast differentiation and function.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  Bone       Date:  2020-06-08       Impact factor: 4.398

2.  Antisense oligonucleotides targeting Notch2 ameliorate the osteopenic phenotype in a mouse model of Hajdu-Cheney syndrome.

Authors:  Ernesto Canalis; Tamar R Grossman; Michele Carrer; Lauren Schilling; Jungeun Yu
Journal:  J Biol Chem       Date:  2020-01-28       Impact factor: 5.157

Review 3.  The Skeleton of Lateral Meningocele Syndrome.

Authors:  Ernesto Canalis
Journal:  Front Genet       Date:  2021-01-14       Impact factor: 4.599

4.  Activation of Notch3 in osteoblasts/osteocytes causes compartment-specific changes in bone remodeling.

Authors:  Ernesto Canalis; Stefano Zanotti; Lauren Schilling; Tabitha Eller; Jungeun Yu
Journal:  J Biol Chem       Date:  2021-03-24       Impact factor: 5.157

Review 5.  Progress and Current Status in Hajdu-Cheney Syndrome with Focus on Novel Genetic Research.

Authors:  Natsuko Aida; Tatsukuni Ohno; Toshifumi Azuma
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

Review 6.  Distinct severity of phenotype in Hajdu-Cheney syndrome: a case report and literature review.

Authors:  Chunhua Zeng; Yunting Lin; Zhikun Lu; Zhen Chen; Xiaoling Jiang; Xiaojian Mao; Zongcai Liu; Xinshuo Lu; Kangdi Zhang; Qiaoli Yu; Xiaoya Wang; Yonglan Huang; Li Liu
Journal:  BMC Musculoskelet Disord       Date:  2020-03-06       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.